ResearcherUniversity of KentuckyActive in the last 2 years
Hannah G. McDonald
Matched on ORCID iD 0000-0002-4523-907X; OpenAlex author ID A5011098073. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 9
2024: 2 papers · 2025: 1 paper · 2026: 1 paper
Papers 4
- Case Report: Prolonged response to cabozantinib and pembrolizumab in treatment-refractory metastatic pancreatic ductal adenocarcinoma. First author DOI 10.3389/fonc.2026.1675133↗
- Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer. Co-author DOI 10.1002/1878-0261.70062↗
- Development of a Novel Protocol for Germline Testing in Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-16011-3↗
- Treatment at an Academic Medical Center Eliminates Survival Disparities for Appalachian Kentuckians with Pancreatic Ductal Adenocarcinoma. First author DOI 10.13023/jah.0601.02↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Michael J. Cavnar · 4 shared papers, 2024–2026 · strength 0.80
- Paper Case Report: Prolonged response to cabozantinib and pembrolizumab in treatment-refractory metastatic pancreatic ductal … DOI 10.3389/fonc.2026.1675133↗
- Paper Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cance… DOI 10.1002/1878-0261.70062↗
- Paper Treatment at an Academic Medical Center Eliminates Survival Disparities for Appalachian Kentuckians with Pancreatic Duc… DOI 10.13023/jah.0601.02↗
- Joseph Kim · 4 shared papers, 2024–2026 · strength 0.80
- Paper Case Report: Prolonged response to cabozantinib and pembrolizumab in treatment-refractory metastatic pancreatic ductal … DOI 10.3389/fonc.2026.1675133↗
- Paper Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cance… DOI 10.1002/1878-0261.70062↗
- Paper Treatment at an Academic Medical Center Eliminates Survival Disparities for Appalachian Kentuckians with Pancreatic Duc… DOI 10.13023/jah.0601.02↗
- Anna M. Reagan · 3 shared papers, 2024–2026 · strength 0.61
- Paper Case Report: Prolonged response to cabozantinib and pembrolizumab in treatment-refractory metastatic pancreatic ductal … DOI 10.3389/fonc.2026.1675133↗
- Paper Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cance… DOI 10.1002/1878-0261.70062↗
- Paper Development of a Novel Protocol for Germline Testing in Pancreatic Cancer. DOI 10.1245/s10434-024-16011-3↗
- Reema Anil Patel · 3 shared papers, 2024–2026 · strength 0.60
- Paper Case Report: Prolonged response to cabozantinib and pembrolizumab in treatment-refractory metastatic pancreatic ductal … DOI 10.3389/fonc.2026.1675133↗
- Paper Treatment at an Academic Medical Center Eliminates Survival Disparities for Appalachian Kentuckians with Pancreatic Duc… DOI 10.13023/jah.0601.02↗
- Paper Development of a Novel Protocol for Germline Testing in Pancreatic Cancer. DOI 10.1245/s10434-024-16011-3↗
- Megan M. Harper · 3 shared papers, 2024–2025 · strength 0.56
- Paper Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cance… DOI 10.1002/1878-0261.70062↗
- Paper Treatment at an Academic Medical Center Eliminates Survival Disparities for Appalachian Kentuckians with Pancreatic Duc… DOI 10.13023/jah.0601.02↗
- Paper Development of a Novel Protocol for Germline Testing in Pancreatic Cancer. DOI 10.1245/s10434-024-16011-3↗
- Emily Cassim · 2 shared papers, 2024 · strength 0.36
- Erin E. Burke · 2 shared papers, 2024 · strength 0.36
- Mei Gao · 1 shared paper, 2025 · strength 0.20
- Chelsey Mckenna Williams · 1 shared paper, 2024 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.